Interstitial lung abnormalities in treatment-naive advanced NSCLC patients (pts): Prevalence and impact on survival.
Mizuki Nishino
No relevant relationships to disclose
Stephanie Cardarella
No relevant relationships to disclose
Suzanne Eleanor Dahlberg
No relevant relationships to disclose
Tetsuro Araki
No relevant relationships to disclose
Christine A. Lydon
No relevant relationships to disclose
Michael S. Rabin
No relevant relationships to disclose
Hiroto Hatabu
No relevant relationships to disclose
Bruce E. Johnson
Consultant or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; GE Healthcare; Genentech; Novartis; Pfizer; Transgenomic
Stock Ownership - KEW Group
Other Remuneration - Postmarketing royalties for EGFR mutation testing from Dana-Farber Cancer Institute